Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall good alignment with the prescribing information. Most core claims (mechanism, indications, dosing considerations, key warnings about sedation and interactions, and overdose guidance) are supported. Notable gaps include absence of explicit second-generation antihistamine labeling, lack of some administration and cost/availability details, and several claims that are not fully supported or are borderline partial (e.g., seasonal vs perennial rhinitis and generic availability).
Category Scores
Accurate Statements
Levocetirizine is an antihistamine.
12.1
Levocetirizine is used to relieve allergy symptoms.
1.1, 1.2
Levocetirizine is commonly prescribed for hives (urticaria).
1.2
Levocetirizine blocks histamine at H1 receptors.
12.1
Levocetirizine reduces allergy-related symptoms.
1.1, 1.2
Drowsiness can still occur with levocetirizine in some people.
5.1
Common side effects include drowsiness or fatigue.
5.1
Caution about driving or operating machinery is advised until you know how you respond.
5.1, 17
Dosing depends on indication, patient age, and kidney function.
17, 8.6
Clinicians may adjust the dose in people with impaired kidney function.
8.6
Antihistamines like levocetirizine are cleared through the body.
12.3
Levocetirizine can cause drowsiness in some users.
5.1
Combining levocetirizine with other medicines that cause sedation can increase fatigue or impairment.
5.1
Alcohol may add to sedation with levocetirizine.
5.1
Safety during pregnancy or breastfeeding depends on timing and individual risk factors.
8.1, 8.2
Overdosage has been reported with XYZAL.
10
Symptoms of overdose may include drowsiness in adults.
10
In children agitation and restlessness may initially occur, followed by drowsiness.
10
There is no known specific antidote to XYZAL.
10
Should overdose occur, symptomatic or supportive treatment is recommended.
10
XYZAL is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested.
10
Unsupported Statements
Levocetirizine is a second-generation antihistamine.
Label does not explicitly classify levocetirizine as second-generation.
Levocetirizine is commonly prescribed for allergic rhinitis (seasonal or perennial).
Label specifies perennial rhinitis (1.1) but does not confirm seasonal indication; not fully supported.
Second-generation antihistamines tend to cause less sedation than many first-generation antihistamines.
No comparative sedation claim is presented in the label sections provided.
Dry mouth is a common adverse effect.
Dry mouth is not listed as a common adverse effect in the provided label sections.
Dizziness or headache are common adverse effects.
Dizziness/headache are not explicitly listed in the provided label sections.
Some people may feel sleepy even with second-generation antihistamines.
No explicit statement about sleep risk specific to second-generation antihistamines in the label.
Levocetirizine is widely available.
Label sections provided do not discuss product availability.
Levocetirizine often comes as a generic.
Label sections provided do not discuss generic status.
Generic levocetirizine typically lowers cost versus brand-name options.
No cost/price information in the provided label.
Exact pricing depends on country, formulation, and dose.
No pricing information in the provided label.
Dosing decisions during pregnancy or breastfeeding usually follow guideline-based recommendations and clinician judgment.
No explicit statement in the label about guideline-based dosing during pregnancy/breastfeeding.
Administration instructions such as 'with or without food' are not specified.
Label states administration can be with or without food, but the AI claim did not explicitly include this detail.
Contradictions
Important Omissions
Explicit labeling of second-generation antihistamine classification and any explicit statement regarding generic availability and cost is not present in the AI claims.
Importance:
Moderate
Administration guidance such as 'can be taken with or without food' is not stated in the AI claims (though present in label).
Importance:
Moderate
Explicit pregnancy/breastfeeding dosing guidance wording in the AI claims (beyond safety statements) is not shown.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Sedation is possible but generally low-risk; warnings cover CNS effects, renal impairment, and interactions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Clarify second-generation antihistamine labeling and provide precise dosing/administration details (including food effects) and availability status.
Suggested Improvement
Incorporate explicit labeling language that levocetirizine is an antihistamine with H1 selectivity, confirm classification as second-generation if applicable, and include comprehensive, age- and condition-specific dosing guidance (including pregnancy/lactation dosing language). Ensure statements about generic availability and pricing are either included or clearly marked as non-label information.